Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean

PHASE3CompletedINTERVENTIONAL
Enrollment

11,000

Participants

Timeline

Start Date

March 15, 2018

Primary Completion Date

July 24, 2021

Study Completion Date

October 29, 2021

Conditions
Obstetrical ComplicationsHemorrhageLabor and Delivery
Interventions
DRUG

Tranexamic Acid

A single dose of Tranexamic Acid (1 gram) in normal saline for a total of 50cc, administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)

DRUG

Placebo

50 cc normal saline administered intravenously immediately following umbilical cord clamping (or as soon as possible afterward)

Trial Locations (12)

10032

Columbia University, New York

15213

Magee Women's Hospital of UPMC, Pittsburgh

19104

Hospital of the University of Pennsylvania, Philadelphia

27599

University of North Carolina - Chapel Hill, Chapel Hill

35233

University of Alabama - Birmingham, Birmingham

43210

Ohio State University Hospital, Columbus

44109

Case Western Reserve-MetroHealth, Cleveland

60611

Northwestern University-Prentice Hospital, Chicago

77030

University of Texas - Houston, Houston

77555

University of Texas Medical Branch, Galveston

84132

University of Utah Medical Center, Salt Lake City

02905

Brown University, Providence

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

The George Washington University Biostatistics Center

OTHER

NCT03364491 - Tranexamic Acid for the Prevention of Obstetrical Hemorrhage After Cesarean | Biotech Hunter | Biotech Hunter